EpiCast Report: Prostate Cancer – Epidemiology Forecast to 2026
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Prostate cancer is a malignancy in the prostate gland, which is located below the bladder and in front of the rectum in males. Worldwide, about 1.1 million men were diagnosed with prostate cancer in 2012. Diagnosed incident cases of prostate cancer is defined as malignant neoplasms with the prostate gland as the primary site (ICD-10 code C61, ICD-O-3 code C61.9). The forecast relies on data from national cancer registries, peer-reviewed journal articles, and primary market research. CRPC was defined as an increase in PSA levels after hormone therapy. Stage at diagnosis is classified according to the American Joint Committee on Cancer (AJCC) groupings, which are based on Tumor/Node/Metastasis (TNM) staging, Gleason score, and PSA level (AJCC, 2009).
In 2016, there were 470,099 diagnosed incident cases of prostate cancer in the 7MM. The US had the most cases with 153,623, or 32.68% of cases in the 7MM, followed by Japan (104,389, 22.21% of cases). The number of cases in the 7MM is expected to grow to 548,394 in 2026, for an Annual Growth Rate (AGR) of 1.67%. In 2016, there were 4,452,307 prevalent cases of prostate cancer diagnosed in the previous 10 years in the 7MM. The US made up the largest share of prevalent cases with 1,872,922, or 42.07% of cases in the 7MM. Japan had the next highest number of cases with 698,512, followed by Germany with 542,521. The number of 10-year prevalent cases in the 7MM is expected to increase to 4,634,443 by 2026, for an AGR of 0.41% per year.
Scope
The Prostate Cancer EpiCast Report and EpiCast Model provide an overview of the risk factors and global trends for prostate cancer in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
It includes a 10-year epidemiological forecast for diagnosed incident cases of prostate cancer in men segmented by age (beginning at 35 years), stage at diagnosis (stage I, II, III, and IV), and risk of biochemical recurrence (low, intermediate, and high) in these markets. Additionally, this report forecasts 10-year prevalent cases of prostate cancer segmented by castration resistance, metastases, and HRD mutations.
The prostate cancer epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
The EpiCast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.
Reasons to Buy
The Prostate Cancer EpiCast series will allow you to:
Develop business strategies by understanding the trends shaping and driving the global prostate cancer market.
Quantify patient populations in the global prostate cancer market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for prostate cancer therapeutics in each of the markets covered.
Understand magnitude of prostate cancer population by risk of biochemical recurrence, castration resistance, metastasis, and HRD mutations.
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.